All In Biotech

Drug Trial Radar · NCT07941362

177Lu-ACT319 in FAP Expressing Solid Tumors

A Phase 1/2 Study of 177Lu-ACT319 in Patients With Advanced FAP Expressing Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

182

Planned (sponsor's estimate)

Start

Oct 25, 2026

Primary completion

Jul 31, 2029

Study completion Nov 2, 2031

Sponsor

Lead sponsor
Actithera INC.Industry
Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study of 177Lu -ACT319 in participants with the following cancers: pancreatic ductal adenocarcinoma (PDAC), biliary tract carcinoma (BTC), that is advanced, and for which there are no valid treatment options. Participants must have cancer that expresses protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, how the body tolerates, and how well ACT319 works in treating cancer. In addition, this study will evaluate how much 177Lu-ACT319 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last approximately 2 years. A separate group of patients with other FAP expressing solid tumor types will be evaluated by PET/CT or SPECT/CT imaging for the intensity of target expression.

Conditions

  • FAP-expressing Solid Tumors
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Biliary Tract Carcinoma (BTC)

Interventions

  • 177Lu-ACT319Drug

    At Dose level 1

  • 177Lu-ACT319Drug

    At Dose Level 2

  • 177Lu-ACT319Drug

    At Dose Level 3

  • 177Lu-ACT319Drug

    At Dose Level 4

  • [18F]-FAPI-74 for imagingDrug

    Low Dose \[18F\]-FAPI-74 for PET/CT imaging in Part 1B

  • 177Lu-ACT319 for imagingDrug

    Low Dose 177Lu-ACT319 for imaging in Part 1B

  • 177Lu-ACT319 at RDEDrug

    177Lu-ACT319 at Recommended Dose for Expansion

  • 177Lu-ACT319 at RDE-1Drug

    177Lu-ACT319 at one level lower than at Recommended Dose for Expansion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose escalation (Part 1A)Time frame: First 42 days of Cycle 1
  2. Imaging/Dosimetry Sub-study (Part 1B)Time frame: 2 days post drug administration
  3. Dose optimization and expansion (Part 2A/2B)Time frame: Up to 12 months after the last treatment.
  4. Dose escalation (Part 1A)Time frame: Up to 24 months from the first treatment cycle administration.
  5. Imaging/Dosimetry Sub-study (Part 1B)Time frame: Up to 8 days.
  6. Dose escalation (Part 1A)Time frame: Up to 24 months from the first treatment cycle administration.
  7. Vital Signs: Change from baseline in systolic blood pressure (Part 1B)Time frame: Up to 8 days.
  8. Vital Signs: Change from baseline in diastolic blood pressure (Part 1B)Time frame: Up to 8 days.
  9. Vital Signs: Change from baseline in pulse rate (Part 1B)Time frame: Up to 8 days.
  10. Vital Signs: Change from baseline in respiratory rate (Part 1B)Time frame: Up to 8 days.
  11. Vital Signs: Change from baseline in body temperature (Part 1B)Time frame: Up to 8 days.
  12. ECGs: Change from baseline in ECG heart rate (Part 1B)Time frame: Up to 8 days.
  13. ECGs: Change from baseline in ECG PR interval (Part 1B)Time frame: Up to 8 days.
  14. ECGs: Change from baseline in ECG QRS duration (Part 1B)Time frame: Up to 8 days.
  15. ECGs: Change from baseline in ECG QT interval (Part 1B)Time frame: Up to 8 days.
  16. Imaging sub-study (Part 1B): Number of participants with clinically significant laboratory abnormalitiesTime frame: Up to 8 days.
  17. ECGs: Change from baseline in Fridericia-corrected QT interval (QTcF) (Part 1B)Time frame: Up to 8 days.
  18. Dose escalation (Part 1A)Time frame: First 42 days of Cycle 1
  19. Vital Signs: Change from baseline in systolic blood pressure (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
  20. Vital Signs: Change from baseline in diastolic blood pressure (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
  21. Vital Signs: Change from baseline in pulse rate (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
  22. Vital Signs: Change from baseline in respiratory rate (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
  23. Vital Signs: Change from baseline in body temperature (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
  24. ECGs: Change from baseline in ECG heart rate (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
  25. ECGs: Change from baseline in ECG PR interval (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
  26. ECGs: Change from baseline in ECG QRS duration (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
  27. ECGs: Change from baseline in ECG QT interval (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
  28. ECGs: Change from baseline in Fridericia-corrected QT interval (QTcF) (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
  29. ECOG: Change from baseline in ECOG performance status (Part 1A, 2A, 2B)Time frame: Up to 24 months from the first treatment cycle administration.
  30. Dose Escalation (Part 1A): Number of participants with clinically significant laboratory abnormalitiesTime frame: Up to 24 months from the first treatment cycle administration
  31. Dose optimization and expansion (Part 2A)Time frame: Up to 24 months.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.